Company intelligence / Profile preview

Immune Biosolutions

Sherbrooke, Quebec, Canadaimmunebiosolutions.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Immune Biosolutions has completed Phase I/II clinical trials of IBIO123, an inhaled antibody therapy for COVID‑19. In a double-blind trial with non-hospitalized adults during the Omicron wave, IBIO123 showed a higher rate of symptom resolution at day eight compared to placebo. The product demonstrated efficacy against all known variants in laboratory assays. Other programs are in preclinical or discovery stages targeting cancer and infectious diseases.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Avian antibodies (IgY)Human antibodies (including monoclonal and bispecific antibodies)
Industry: Biotech

Drug pipeline

3 assets

IBIO123

2 more assets in the full pipeline.

Partnerships

Centre hospitalier universitaire de Montréal (CHUM)CHU Sainte‑Justine research centers in Montreal

Beyond the preview

Go deeper on Immune Biosolutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immune Biosolutions.